Overview
- Lilly reported a blowout quarter on Aug. 5 with $23.0 billion in revenue, a 48% year‑over‑year rise, and raised full‑year guidance to $85 billion–$87 billion.
- Mounjaro and Zepbound together drove the surge, producing roughly $14.9 billion in combined sales for the quarter.
- Companywide realized prices fell about 13% and international prices fell as much as 36% after moves like Mounjaro’s addition to China’s reimbursement list, reflecting Lilly’s tradeoff of lower prices for broader access.
- Policy and product moves are widening the market: Medicare’s GLP‑1 Bridge expanded coverage to roughly 20 million beneficiaries, Lilly has filed oral Foundayo in more than 40 countries with an early‑2027 international rollout planned, and positive Phase III retatrutide results set up a planned U.S. filing in Q1 2027.
- Lilly is investing in manufacturing and acquisitions to support scale, but the company’s outlook now hinges on whether rising global volumes can outpace continued price erosion to make growth durable.